Robert H. Lurie Cancer Center

How to interpret these research links

Connected source records

The exact organization name Robert H. Lurie Cancer Center appears in 6 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials6

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

6 shown

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast CancerNCT00080613 · lead sponsor

WITHDRAWN

Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)NCT05056077 · collaborator · 2021-10-21

ACTIVE_NOT_RECRUITING

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerNCT01259089 · collaborator · 2011-04-27

COMPLETED

Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast CancerNCT01259076 · collaborator · 2011-02-01

TERMINATED

Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast CancerNCT01060514 · collaborator · 2010-02-01

TERMINATED

Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast CancerNCT01081106 · collaborator

WITHDRAWN

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Robert H. Lurie Cancer Center as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

erlotinib hydrochloride1

exemestane1

pazopanib1

vinorelbine1

erlotinib hydrochloride RxCUI 477320 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial exemestane RxCUI 258494 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pazopanib RxCUI 714438 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial vinorelbine RxCUI 39541 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator5

lead sponsor1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.